Werewolf Therapeutics (NASDAQ:HOWL) Announces Earnings Results

Werewolf Therapeutics (NASDAQ:HOWL) posted its quarterly earnings data on Friday. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.36, FiscalAI reports. The business had revenue of $21.00 million during the quarter.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock opened at $0.35 on Friday. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $2.38. The stock has a market capitalization of $17.16 million, a P/E ratio of -0.46 and a beta of 0.30. The stock has a fifty day moving average of $0.39 and a 200-day moving average of $0.60.

Insider Buying and Selling at Werewolf Therapeutics

In related news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the sale, the insider directly owned 303,719 shares of the company’s stock, valued at $106,301.65. This trade represents a 57.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total value of $33,302.99. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 3,634,670 shares of company stock valued at $1,751,888. 23.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HOWL. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $409,000. Renaissance Technologies LLC grew its position in Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares during the last quarter. Citadel Advisors LLC bought a new stake in Werewolf Therapeutics during the 3rd quarter worth $304,000. Vanguard Group Inc. increased its holdings in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Werewolf Therapeutics in the 2nd quarter worth about $113,000. 64.84% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Wall Street Zen raised shares of Werewolf Therapeutics to a “sell” rating in a report on Saturday. Weiss Ratings cut Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.